Yang, L. H., Phillips, M. R., Li, X., Yu, G., Grivel, M. M., Zhang, J., Shi, Q., Ding, Z., Pang, S., & Susser, E. (2022). Determinants of never-treated status in rural versus urban contexts for individuals with schizophrenia in a population-based study in China. BMC Psychiatry, 22(1). https://doi.org/10.1186/s12888-021-03651-y

Deckler, E., Ferland, M., Brazis, S., Mayer, M. R., Carlson, M., & Kantrowitz, J. T. (2022). Challenges and Strategies for the Recruitment of Patients With Schizophrenia in a Research Setting. International Journal of Neuropsychopharmacology, 25(11), 924–932. https://doi.org/10.1093/ijnp/pyac058

Ibarra‐Lecue, I., Unzueta‐Larrinaga, P., Barrena‐Barbadillo, R., Villate, A., Horrillo, I., Mendivil, B., Landabaso, M. A., Meana, J. J., Etxebarria, N., Callado, L. F., & Urigüen, L. (2022). Cannabis use selectively modulates circulating biomarkers in the blood of schizophrenia patients. Addiction Biology, 27(6). Portico. https://doi.org/10.1111/adb.13233

Lynch, D. A., Brown, M., Saperstein, A., Stefancic, A., & Medalia, A. (2022). Assessing metamotivation in schizophrenia: A pilot study of the Brief Regulation of Motivation Scale (BRoMS). Psychiatry Research, 317, 114799. https://doi.org/10.1016/j.psychres.2022.114799

Tarricone, I., D’Andrea, G., Jongsma, H. E., Tosato, S., Gayer-Anderson, C., Stilo, S. A., Suprani, F., Iyegbe, C., van der Ven, E., Quattrone, D., di Forti, M., Velthorst, E., Rossi Menezes, P., Arango, C., Parellada, M., Lasalvia, A., La Cascia, C., Ferraro, L., Bobes, J., … Morgan, C. (2021). Migration history and risk of psychosis: results from the multinational EU-GEI study. Psychological Medicine, 52(14), 2972–2984. https://doi.org/10.1017/s003329172000495x

Gao, Y. N., & Olfson, M. (2022). National trends in metabolic risk of psychiatric inpatients in the United States during the atypical antipsychotic era. Schizophrenia Research, 248, 320–328. https://doi.org/10.1016/j.schres.2022.09.023

Cullen, M. B. R., Meiser, B., Barlow-Stewart, K., Green, M., Appelbaum, P. S., Carr, V. J., Cairns, M. J., Lebowitz, M. S., & Kaur, R. (2022). Perceptions of causal attribution and attitudes to genetic testing among people with schizophrenia and their first-degree relatives. European Journal of Human Genetics, 30(10), 1147–1154. https://doi.org/10.1038/s41431-022-01116-8

Benoit, L. J., Canetta, S., & Kellendonk, C. (2022). Thalamocortical Development: A Neurodevelopmental Framework for Schizophrenia. Biological Psychiatry, 92(6), 491–500. https://doi.org/10.1016/j.biopsych.2022.03.004

Cheslack-Postava, K., & Brown, A. S. (2022). Prenatal infection and schizophrenia: A decade of further progress. Schizophrenia Research, 247, 7–15. https://doi.org/10.1016/j.schres.2021.05.014

Marrie, R. A., Allegretta, M., Barcellos, L. F., Bebo, B., Calabresi, P. A., Correale, J., Davis, B., De Jager, P. L., Gasperi, C., Greenbaum, C., Helme, A., Hemmer, B., Kanellis, P., Kostich, W., Landsman, D., Lebrun-Frenay, C., Makhani, N., Munger, K. L., Okuda, D. T., … Tremlett, H. (2022). From the prodromal stage of multiple sclerosis to disease prevention. Nature Reviews Neurology, 18(9), 559–572. https://doi.org/10.1038/s41582-022-00686-x

Chand, G. B., Singhal, P., Dwyer, D. B., Wen, J., Erus, G., Doshi, J., Srinivasan, D., Mamourian, E., Varol, E., Sotiras, A., Hwang, G., Dazzan, P., Kahn, R. S., Schnack, H. G., Zanetti, M. V., Meisenzahl, E., Busatto, G. F., Crespo-Facorro, B., Pantelis, C., … Davatzikos, C. (2022). Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population. American Journal of Psychiatry, 179(9), 650–660. https://doi.org/10.1176/appi.ajp.21070686

Szeszko, P. R., Gohel, S., Vaccaro, D. H., Chu, K.-W., Tang, C. Y., Goldstein, K. E., New, A. S., Siever, L. J., McClure, M., Perez-Rodriguez, M. M., Haznedar, M. M., Byne, W., & Hazlett, E. A. (2022). Frontotemporal thalamic connectivity in schizophrenia and schizotypal personality disorder. Psychiatry Research: Neuroimaging, 322, 111463. https://doi.org/10.1016/j.pscychresns.2022.111463

Benoit, L. J., Holt, E. S., Posani, L., Fusi, S., Harris, A. Z., Canetta, S., & Kellendonk, C. (2022). Adolescent thalamic inhibition leads to long-lasting impairments in prefrontal cortex function. Nature Neuroscience, 25(6), 714–725. https://doi.org/10.1038/s41593-022-01072-y

Javitt, D. C., & Kantrowitz, J. T. (2022). The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to disease. Schizophrenia Research, 242, 56–61. https://doi.org/10.1016/j.schres.2022.01.013

Martínez-Alés, G., & Susser, E. S. (2022). A useful construct to improve the lives of people with schizophrenia. Schizophrenia Research, 242, 91–93. https://doi.org/10.1016/j.schres.2021.12.010

Stone, W. S., Phillips, M. R., Yang, L. H., Kegeles, L. S., Susser, E. S., & Lieberman, J. A. (2022). Neurodegenerative model of schizophrenia: Growing evidence to support a revisit. Schizophrenia Research, 243, 154–162. https://doi.org/10.1016/j.schres.2022.03.004

First, M. B., & Lieberman, J. A. (2022). How should we diagnose schizophrenia: Don’t throw the baby out with the bath water. Schizophrenia Research, 242, 81–83. https://doi.org/10.1016/j.schres.2022.01.024

Alkelai, A., Greenbaum, L., Docherty, A. R., Shabalin, A. A., Povysil, G., Malakar, A., Hughes, D., Delaney, S. L., Peabody, E. P., McNamara, J., Gelfman, S., Baugh, E. H., Zoghbi, A. W., Harms, M. B., Hwang, H.-S., Grossman-Jonish, A., Aggarwal, V., Heinzen, E. L., Jobanputra, V., … Goldstein, D. B. (2021). The benefit of diagnostic whole genome sequencing in schizophrenia and other psychotic disorders. Molecular Psychiatry, 27(3), 1435–1447. https://doi.org/10.1038/s41380-021-01383-9

Sehatpour, P., Javitt, D. C., De Baun, H. M., Carlson, M., Beloborodova, A., Margolin, D. H., Carlton, M. B. L., Brice, N. L., & Kantrowitz, J. T. (2021). Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058. Neuropsychopharmacology, 47(3), 711–718. https://doi.org/10.1038/s41386-021-01170-8

Jutla, A., Foss‐Feig, J., & Veenstra‐VanderWeele, J. (2021). Autism spectrum disorder and schizophrenia: An updated conceptual review. Autism Research, 15(3), 384–412. Portico. https://doi.org/10.1002/aur.2659

Zoghbi, A. W., Dhindsa, R. S., Goldberg, T. E., Mehralizade, A., Motelow, J. E., Wang, X., Alkelai, A., Harms, M. B., Lieberman, J. A., Markx, S., & Goldstein, D. B. (2021). High-impact rare genetic variants in severe schizophrenia. Proceedings of the National Academy of Sciences, 118(51). https://doi.org/10.1073/pnas.2112560118

Ku, B. S., Compton, M. T., Walker, E. F., & Druss, B. G. (2021). Social Fragmentation and Schizophrenia. The Journal of Clinical Psychiatry, 83(1). https://doi.org/10.4088/jcp.21r13941

Salgado-Pineda, P., Rodriguez-Jimenez, R., Moreno-Ortega, M., Dompablo, M., Martínez de Aragón, A., Salvador, R., McKenna, P. J., Pomarol-Clotet, E., & Palomo, T. (2021). Activation and deactivation patterns in schizophrenia during performance of an fMRI adapted version of the stroop task. Journal of Psychiatric Research, 144, 1–7. https://doi.org/10.1016/j.jpsychires.2021.09.039

Lahera, G., Reboreda, A., Vallespí, A., Vidal, C., López, V., Aznar, A., Fernández, P., Escolar, M., Martínez-Alés, G., Rodriguez-Jimenez, R., Halverson, T., Frommann, N., Wölwer, W., & Penn, D. L. (2021). Social Cognition and Interaction Training (SCIT) versus Training in Affect Recognition (TAR) in patients with schizophrenia: A randomized controlled trial. Journal of Psychiatric Research, 142, 101–109. https://doi.org/10.1016/j.jpsychires.2021.07.029